27 November 2024 : Clinical Research
Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms
Marzena Jabczyk
1ABDEF, Justyna Nowak 2ABCDE*, Sylwia Mielcarska 3CD, Bartosz Hudzik 2AC, Kinga Wołkowska-Pokrywa 3B, Elżbieta Świętochowska 3BC, Barbara Zubelewicz-Szkodzińska 14ABEFG
DOI: 10.12659/MSM.945899
Med Sci Monit 2024; 30:e945899
Table 5 Comparison of atherogenic indices between the SCORE2 and SCORE2-OP groups.
| Parameter | CVD risk based on SCORE-OP/SCORE-OP2 | P value | ||
|---|---|---|---|---|
| Low and moderate risk (N=16) | High risk (N=28) | Very high risk (N=62) | ||
| Castelli’s risk index-I | 3.83 (3.23–4.46) | 3.06 (2.30–3.91) | 3.35 (2.49–4.77) | 0.15 |
| Castelli’s risk index-II | 2.43 (1.94–2.96) | 1.74 (1.12–2.53) | 2.06 (1.28–3.12) | 0.12 |
| Atherogenic Index of plasma (AIP) | −0.07±0.25 | −0.13±0.28 | −0.09±0.29 | 0.84 |
| Atherogenic coefficient (AC) | 2.83 (2.23–3.46) | 2.07 (1.30–2.91) | 2.35 (1.49–3.77) | 0.15 |
| Lipoprotein combine index (LCI) | 12.0 (10.28–28.86) | 12.09 (4.52–18.89) | 14.53 (5.03–26.49) | 0.65 |
| TG/HDL-C ratio | 1.90 (1.25–2.57) | 1.69 (1.16–2.44) | 1.76 (1.11–3.04) | 0.8122 |
| METS-IR | 42.47±9.96 | 37.48 (33.89–41.52) | 38.52 (34.19–45.55) | 0.53 |
| TyG Index | 8.56±0.41 | 8.67±0.52 | 8.65±0.52 | 0.57 |
| TyG BMI index | 250.25 (207.95–293.39) | 240.21 (214.38–261.75) | 238.94 (208.03–270.25) | 0.89 |
| TG/HDL ratio – the triglyceride/high-density lipoprotein cholesterol ratio; METS-IR – metabolic score for insulin resistance; TyG index – triglyceride-glucose index; TyG BMI index – triglyceride-glucose-body mass index. Kruskall-Wallis test with the post hoc multiple comparison test. | ||||